Apr 7, 2022 | Press release
Södertälje, Sweden, 7th April 2022 – Anocca, a biotechnology company using its precision biology platforms to engineer a broad portfolio of innovative T cell therapeutics, today announced the appointment of Dr. Michael Kalos to its Scientific Advisory Board (SAB). Dr....
Feb 22, 2022 | Press release
Södertälje, Sweden, February 22, 2022 – Anocca AB, a pioneer in T cell immunotherapy, today announces it has made a number of appointments to expand its senior leadership team and strengthen its business development and R&D capabilities. This includes the...
Dec 16, 2021 | Anocca in the news
Originally published in BioCentury. Anocca is using engineered human cells to recapitulate the T cell immune system ex vivo, eliminating the person-to-person variability in working with primary T cells from patients, to create standardized, scalable TCR-modified T...
